Thermo Fisher Scientific event puts specialty diagnostics in focus

Thermo Fisher Scientific (TMO) has put its specialty diagnostics business in the spotlight after showcasing new products and recent U.S. Food and Drug Administration clearances at the ADLM conference in Anaheim in late July 2026.

The event highlighted the EXENT Solution for multiple myeloma monitoring and the EliA CTD 13 Screen for autoimmune disease testing, along with software and quality control tools designed to support faster and more reliable results in clinical laboratories worldwide.

The ADLM announcements come after a period of strong momentum for Thermo Fisher Scientific, with a 30-day share price return of 16.44% and a 90-day share price return of 27.74%, contributing to a 1-year total shareholder return of 29.40%.

If you are interested in how diagnostics and life sciences trends connect to other listed companies, this could be a useful moment to scan 43 healthcare AI stocks

After a sharp move that has put Thermo Fisher Scientific near US$594 a share and delivered a 1 year total return close to 30%, the obvious tension is clear: does the current setup still reward new risk, or mostly those already in early?

Most popular Thermo Fisher Scientific narrative: 0.5% overvalued

Thermo Fisher Scientific closed at $594, compared with a most followed narrative fair value estimate of about $590.77. This points to a very small premium that keeps attention on the underlying growth story rather than any big pricing gap.

Strong momentum in high impact innovation, evidenced by next generation analytical tools like the Orbitrap mass spectrometers and AI integration into drug development workflows, positions Thermo Fisher to capture incremental share as genomics and precision medicine proliferate, structurally boosting future revenues and margins.

Curious what sits behind that growth pitch. The narrative leans on specific revenue and earnings paths, margin gains and a future earnings multiple. The exact mix of those assumptions is what really drives that $590.77 fair value call.

Result: Fair Value of $590.77 (OVERVALUED)

However, Thermo Fisher Scientific still faces questions around academic and China demand, and any extended weakness in these budgets could quickly challenge the current growth pitch.

Another view of Thermo Fisher Scientific’s valuation

The most followed narrative pegs Thermo Fisher Scientific at a small premium to its fair value estimate. Our DCF model points in the opposite direction. On this measure, TMO at $594 screens about 7.3% below an estimated $640.50 fair value, which presents the current price more as a discount than a stretch.

DCF models rely heavily on long term cash flow assumptions, discount rates and terminal values. If those inputs change, the gap between $594 and $640.50 can close quickly. The key question is which set of assumptions appears more realistic given how you view Thermo Fisher Scientific’s future cash generation.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thermo Fisher Scientific for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of enthusiasm and questions around Thermo Fisher Scientific, this is a good time to review the underlying data yourself and move quickly if needed. To see how the positives and concerns balance out in one place, start with the 3 key rewards and 1 important warning sign.

Looking for more Thermo Fisher Scientific style investment ideas?

If Thermo Fisher Scientific has you thinking about your next move, do not stop here. Use a few minutes today to scan fresh stock ideas that fit clear, disciplined criteria.

• Target potential bargains by checking companies that screen as high quality and currently priced below their assessed value with the 51 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks that combine higher yields with resilient profiles through the 8 dividend fortresses.
• Aim to reduce portfolio shocks by filtering for companies with lower risk scores and consistent fundamentals using the 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.